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ABSTRACT 
 
BACKGROUND Smith-Lemli-Opitz syndrome (SLOS) is a rare disease caused by biallelic 
mutation in the 7-dehydrocholesterol (7DHC) reductase gene. High oxidizability of 7DHC 
and the appearance of small-sized low-density lipoprotein (LDL) subfractions indicate 
increased endogenous oxidative stress that is counterbalanced by natural antioxidant defense 
mechanisms including the high-density lipoprotein (HDL)-associated paraoxonase-1 (PON1) 
enzyme. PON1 prevents lipoproteins from oxidative modifications; however, PON1 activity 
and the distribution of lipoprotein subfractions have not been studied in SLOS. 
METHODS 7DHC levels and PON1 arylesterase activities were measured 
spectrophotometrically in eleven SLOS patients and ten healthy children. Lipoprotein 
subfractions were detected by polyacrylamide gel electrophoresis. 
RESULTS Compared to controls, there was a shift towards the small-dense LDL subfraction 
and the large HDL subfraction in SLOS. PON1 arylesterase activity was significantly 
decreased in SLOS patients and correlated negatively with the proportion of small-dense LDL 
subfraction and the proportion of large HDL subfraction. Significant positive correlations 
were detected between PON1 arylesterase activity and the ratios of intermediate and small 
HDL subfractions. 
CONCLUSIONS Decreased PON1 activity and the deleterious shift in the distribution of 
lipoprotein subfractions may contribute to the impaired antioxidant status observed in SLOS. 
Monitoring of serum PON1 arylesterase activity may be a complementary biomarker in 
SLOS.  
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INTRODUCTION 
 
Cholesterol is an important structural component of cell membranes and serves as a 
precursor of steroid hormones and bile acids.  It is a major constituent of the myelin formed in 
the brain, spinal fluid and in the peripheral nervous system. From all organs, brain is the 
richest in cholesterol, containing approximately 20% of the whole body cholesterol (1). 
Cholesterol is synthesized from lanosterol by a series of oxidations, reductions and 
demethylations (2); therefore it is not surprising that inherited defects of cholesterol 
biosynthesis may lead to numerous diseases. 
Smith-Lemli-Opitz syndrome (SLOS, OMIM 270400) is a rare autosomal recessive 
genetic disease originating from biallelic mutations in the gene encoding 3β-hydroxysterol-
Δ7-reductase (DHCR7, EC 1.3.1.21), which is located on chromosome 11q13. This genetic 
defect is manifested as a large and variable spectrum of phenotypes, including multiple 
congenital malformations, microcephaly, neurological defects, photosensitivity, syndactyly of 
the second and third toes, growth and mental retardation, and behavioral problems (3, 4). For 
phenotypic characterization, the modified Bialer scoring system of Kelley and Hennekam has 
been used weighting embryologically separate organ systems equally (5). DHCR7 enzyme 
catalyzes the reduction of 7-dehydrocholesterol (7DHC) to cholesterol in the last step of 
cholesterol biosynthesis pathway (6). SLOS patients exhibit extremely high levels of 7DHC 
and reduced levels of cholesterol in the tissues, plasma and other fluids. In accordance with 
the results of Tint et al. (7), we previously reported that both the initial value of serum 
cholesterol level and the cholesterol/7DHC ratio had an important prognostic value in the 
severity, development and life expectancy of SLOS children (8). To date, routine therapy has 
been cholesterol supplementation in SLOS; while combined cholesterol-simvastatin therapy 
(9, 10) or cholesterol-antioxidant treatment might also be effective in SLOS patients (11). 
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However, as it was recently reviewed, simvastatin is not recommended for SLOS treatment 
due to its potential side effects (12). High oxidizability of 7DHC has been reported to enhance 
endogenous oxidative stress in cell and animal models of SLOS (13) and in several human 
studies (14). Additionally, inactivation of the endogenous antioxidant defense mechanisms 
may also contribute to increased oxidative stress. Oxidation of the predominantly smaller and 
denser low-density lipoprotein (LDL) particles play a key role in this process (15). Human 
paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with 
significant antioxidant properties preventing lipoproteins from oxidative modification (16). 
PON1 activity was found to diminish in several human diseases characterized by enhanced 
oxidative stress, including coronary artery disease, diabetes mellitus, hyperlipidemia, obesity, 
and several autoimmune diseases (17-20). 
As it was demonstrated recently, high 7DHC level accelerates the formation of 
oxysterols in SLOS resulting in increased cellular susceptibility for oxidative stress (21-22). 
To date, however, there is no data on the distribution of lipoprotein subfractions in SLOS, 
while information about the antioxidant PON1 activity is also lacking in these patients. 
Therefore, we aimed to study the distributions of LDL and HDL subfractions in SLOS 
patients and compared their data to healthy children. We also examined PON1 activities in 
these groups and intended to clarify possible associations between PON1 antioxidant status 
and various lipoprotein subfractions. 
 
 5 
 
RESULTS 
 
 Clinical and laboratory characteristics of study participants are summarized in Table 1. 
Mean SLOS clinical severity score was 30.9±15.1; one child with severe disease (clinical 
severity score>50) died as a newborn, seven patients exhibited typical symptoms (clinical 
severity score 20-50), and three patients had mild features of SLOS group (clinical severity 
score<20). 7DHC level in SLOS patients was 205 (85-274) mg/L, while 7DHC levels were 
below the limit of detection in healthy children (<0.15 mg/L). Mean total cholesterol, LDL-C 
and HDL-C levels were significantly lower in patients with SLOS (p<0.0001, p<0.0001 and 
p<0.01; respectively) compared to healthy children. A strong, significant negative correlation 
was detected between the clinical severity score and HDL-C levels (r=-0.804, p=0.003) 
(Figure 1a). 
Compared to controls, the proportion of large LDL subfraction was significantly lower 
(p<0.001), while the proportion of small-sized, dense LDL subfraction was significantly 
higher (p<0.01) in SLOS patients (Table 1). Furthermore, the mean LDL size was 
significantly lower in patients with SLOS than in healthy children (p<0.001). These data are 
in accordance with the LDL subfraction pattern in these patients: seven SLOS patients 
represented an abnormal LDL pattern; one child had intermediate and only three children had 
normal LDL subfraction pattern. In contrast, none of the control children displayed abnormal 
LDL subfraction pattern, two of them were found to have an intermediate pattern, while the 
remaining eight children represented normal LDL subfraction patterns. Figure 2 demonstrates 
an abnormal subfraction pattern (mean LDL size: 25.34 nm) in a typical SLOS patient (Figure 
2a) and a normal LDL subfraction pattern (mean LDL size: 27.31 nm) in a healthy child 
(Figure 2b). Densitometric scanning of LDL subfractions identified an SLOS patient with 
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predominantly smaller and denser LDL subfractions (shown in red in Figure 2a) indicating an 
increased susceptibility for enhanced oxidative stress in SLOS. On the other hand, Figure 2b 
is a representative sample of lipoprotein subfraction pattern of a healthy child typically with 
rather larger and less dense LDL subfraction pattern (shown in yellow). 
We also detected a shift towards the larger and less dense HDL subfractions in 
children with SLOS (Table 1). The proportion of the large HDL subfractions was significantly 
higher (p<0.001), while proportions of intermediate and small HDL subfractions were 
significantly lower in SLOS children compared to healthy controls (p<0.001 and p<0.01, 
respectively). In Figure 3, we also demonstrate a densitometric scan of HDL subfractions in a 
patient with typical SLOS (Figure 3a) representing the dominance of large HDL subfractions 
and the decreased prevalence of intermediate and small HDL subfractions compared to a 
healthy control child (Figure 3b).  
Serum PON1 paraoxonase activity was lower in the SLOS group compared to 
controls, SLOS: 37.05 (9.98-93.22) U/L vs. controls: 72.85 (42.04-206.93) U/L; p=0.069; 
although the difference was not significant between the two groups. In turn, serum PON1 
arylesterase activity was found to be significantly decreased in SLOS children compared to 
controls (SLOS: 64.30±52.69 U/L vs. controls: 107.93±26.83 U/L; p=0.022) (Figure 1b). 
Examining the correlations between serum PON1 arylesterase activity and lipoprotein 
parameters (Table 2), we detected a significant positive correlation between PON1 
arylesterase activity and total cholesterol level (r=0.543, p=0.045). In addition, there were 
positive, although not significant trends of associations between PON1 arylesterase activities 
and LDL-C concentrations and the proportions of large LDL subfractions, respectively. In 
turn, a significant negative correlation was found between PON1 arylesterase activity and the 
proportion of small-dense LDL subfraction (r=-0.578, p=0.031). Additionally, PON1 
arylesterase activity correlated positively with mean LDL size (r=0.610, p=0.021). 
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Although there was no significant association between PON1 arylesterase activity and 
HDL-C levels; PON1 arylesterase activity correlated negatively with the proportion of large 
HDL subfraction (r=-0.798, p=0.001). In contrast, significant positive correlations were found 
between PON1 arylesterase activities and the proportions of intermediate and small HDL 
subfractions (r=0.652, p=0.012 and r=0.663, p=0.010), respectively. 
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DISCUSSION 
According to our knowledge, this is first report on the distribution of LDL and HDL 
subfractions and the status of HDL-associated antioxidant PON1 activity in SLOS patients. 
Based upon the lipoprotein subfraction analyses, we detected a shift towards the small-dense 
LDL subfraction and the dominance of the large-sized HDL subfraction, which indicate 
disturbed cholesterol biosynthesis in SLOS. Decreased PON1 arylesterase activity and 
elevated levels of 7DHC were also demonstrated in these children, revealing enhanced 
endogenous oxidative stress and impaired antioxidant status. 
Previous studies found altered lipoprotein parameters and impaired cholesterol 
biosynthesis in SLOS (23, 24). Also, initial cholesterol concentrations were found to be 
fundamental in determining severity and life expectancy in SLOS (7, 8). Corroborating 
previous data, significantly decreased total cholesterol, LDL-C and HDL-C levels were 
measured in our patients and we found a significant negative correlation between HDL-C 
level and the clinical severity score, emphasizing the putative role of HDL in the 
pathomechanism of SLOS. 
LDL and HDL are heterogeneous particles consisting multiple lipoprotein 
subpopulations that vary in protein and lipid components, physicochemical properties, particle 
size and density (25). Although lipoprotein levels are essential in the prognosis of SLOS, the 
distributions of LDL and HDL subfractions have not been studied yet. Compared to healthy 
infants, we found an unexpectedly higher proportion of small-dense LDL subfraction and 
lower mean LDL size in children with SLOS. The prevalence of abnormal LDL subfraction 
pattern was 63% in SLOS, whereas none of the healthy children displayed LDL abnormality. 
The latter data are in congruence with the results of the STRIP Study indicating a 1-4% 
prevalence of the small-dense LDL subfraction in healthy children (26). Since the 
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predominantly smaller and denser LDL subfractions are extremely prone to undergo oxidative 
modification (15), their dominance might indicate the presence of oxidative stress in SLOS; 
however, further studies are needed to clarify such association in this disease. 
HDL subpopulations play various roles in lipid metabolism, as large-sized HDL 
subfractions are primarily involved in reverse cholesterol transport - a mechanism by which 
HDL takes up cholesterol in the peripheral tissues and transports it to the liver; while small-
sized HDL subfractions rather exert anti-inflammatory effects protecting LDL from oxidation 
(27, 28). In this study, we observed altered distribution of HDL subfractions in SLOS patients 
who were characterized by a significantly higher proportion of large-sized HDL subfraction 
and lower proportions of intermediate and small-sized HDL subfractions. Based upon these 
results, one may hypothesize that altered distribution of HDL subfractions may reflect 
enhanced reverse cholesterol transport compensating for extremely low cholesterol levels 
found routinely in SLOS. HDL-associated PON1 is widely recognized as one of the major 
antioxidant enzymes of HDL and localized primarily on small-sized HDL subfractions (29, 
30). Diminished PON1 activity was reported in several disease entities involving altered 
redox balance and increased oxidative stress (31). Therefore, lower proportion of small-sized 
HDL subfractions and decreased PON1 arylesterase activity in SLOS patients might be 
related to their impaired synthesis in the liver and they probably indicate a reduced 
antioxidant capacity.  
It must be noted, that PON1 possesses various enzyme activities with different 
substrate specificities including paraoxonase and arylesterase activities. PON1 paraoxonase 
activity is determined by a Q192R polymorphism in the coding region and shows a trimodal 
distribution; therefore, PON1 paraoxonase activity has a large inter-individual variation (up to 
15-40 times) among the general population (31). In contrast, PON1 arylesterase activity is not 
affected by this polymorphism; therefore, this activity is distributed unimodally and reflects 
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protein concentration and antioxidant capacity of PON1 (32, 33). Compared to controls, we 
found a marked but not significant reduction of serum PON1 paraoxonase activity in children 
with SLOS. Presumably due to the relatively small sample size and the trimodal distribution 
of the PON1 paraoxonase activity, we did not detect a difference in this variable between the 
studied groups.  In turn, we demonstrated a significant negative correlation between the 
proportion of oxidizable small-dense LDL subfraction and the antioxidant PON1 arylesterase 
activity. The proportion of large HDL subfraction correlated negatively, while the proportions 
of intermediate and small HDL subfractions correlated positively with PON1 arylesterase 
activity. These correlations support previous observations that small-sized HDL subfraction 
may have the highest PON1 activity (34). Thus, one might conclude that decreased PON1 
arylesterase activity and altered lipoprotein subfractions may serve as novel biomarkers in 
SLOS. 
In line with decreased PON1 arylesterase activity, we also found markedly increased 
levels of 7DHC further enhancing oxidative stress in SLOS. 7HDC is highly disposed to react 
with molecular oxygen, producing over a dozen different oxysterols, such as 3β,5α-
dihydroxycholest-7-en-6-one (DHCEO) in vitro and in vivo (21, 22, 35). Since 7DHC and 
7DHC-derived oxysterols are potent pro-oxidant agents, these molecules may also contribute 
to enhanced lipid peroxidation and protein degradation resulting in reduced antioxidant 
capacity and PON1 activity.  
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CONCLUSION 
Decreased PON1 arylesterase activity and an unfavorable shift in the distribution of 
lipoprotein subfractions may contribute to impaired antioxidant status in SLOS. Monitoring of 
serum PON1 arylesterase activity may serve as a useful complementary biomarker in these 
patients. Further studies are needed to determine the clinical benefits of PON1 arylesterase 
activity measurement in SLOS.  
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PATIENTS AND METHODS 
 
 Study population 
11 children with clinical and biochemical diagnosis of SLOS (aged between 0.1-20 
years, four girls and seven boys) and 10 healthy control children (age of 0.3-19 years, five 
girls and five boys) were enrolled in our study. Besides the presence of characteristic clinical 
symptoms, the diagnosis of SLOS was proven by serum 7DHC level. Anatomical 
abnormalities of ten embryologically separate organs (brain, oral region, limbs, eye, heart, 
kidney, liver, lung, bowel and genitals) have been scored (5). On the basis of the clinical 
severity scores, patients were assigned to three groups: (i) patients with mild SLOS (n=3, 
clinical severity score<20), (ii) typical SLOS (n=7, clinical severity score 20–50) and (iii) 
severe SLOS (n=1, clinical severity score>50). After setting up the diagnosis, all patients 
received cholesterol supplementation (Cholesterol Module, 50–250 mg/kg/day, Nutricia; no 
18.012), which was complemented with simvastatin in nine patients (dosage 0.2–0.4 
mg/kg/day). None of the studied children received dietary and antioxidant supplements and 
were free of clinically significant infectious diseases. All parents provided written informed 
consent. The study protocol was approved by the Ethical Committee of University of 
Debrecen and the study was carried out in accordance with the Helsinki Declaration. 
 
 Sample collection and laboratory measurements 
Venous blood samples were taken after an overnight fasting and sera were separated 
immediately. Routine laboratory parameters were determined from fresh sera with Cobas 
c501 analyzer (Roche Ltd, Mannheim, Germany). Total cholesterol levels were measured by 
using enzymatic, colorimetric tests (cholesteroloxidase, p-aminophenazone – CHOD-PAP). 
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HDL-cholesterol (HDL-C) levels were determined by a homogenous, enzymatic, colorimetric 
assay (Roche HDL-C plus 3rd generation). The rapid determination of serum 7DHC was 
performed by an UV spectrophotometric method as described previously (8). Sera were kept 
frozen at -70°C for subsequent LDL and HDL subfraction analysis and PON1 activity 
measurements. 
 
 LDL subfraction analysis 
LDL subfractions were detected by polyacrylamide gel electrophoresis using the 
Lipoprint System (Quantimetrix Corp., Redondo Beach, CA) according to the manufacturer’s 
instructions. Briefly, 25 μl of serum samples were added to polyacrylamide gel tubes along 
with 200 μl loading gel solution containing Sudan Black as lipophilic dye. After 30 min of 
photopolymerization at room temperature, electrophoresis was performed for one hour with a 
3 mA/gel tube.  
Lipoprotein fractions (bands) were identified after electrophoresis by their mobility 
(Rf) using VLDL as the starting reference point (Rf 0.0) and HDL as the ending reference 
point (Rf 1.0). In between, IDL subfractions (Midband A, B and C) and LDL subfractions 
were distributed from LDL1 to LDL7 (Rf 0.32, 0.38, 0.45, 0.51, 0.56, 0.6, and 0.64, 
respectively). LDL1 and LDL2 bands corresponded to the larger, buoyant LDL subclasses 
(designed as normal “Pattern A”), whereas bands from LDL3 to LDL7 represented the 
predominantly smaller, denser LDL subclasses (designed as abnormal “Pattern B”). 
Percentages of the area under the curve (AUC%) were calculated with Lipoware computer 
software (Quantimetrix Corp., Redondo Beach, CA). Proportion of large LDL (large LDL%) 
was defined as the sum of the percentage of LDL1 and LDL2, whereas proportion of small 
LDL (small LDL%) was defined as the sum of LDL3 to LDL7. Cholesterol concentrations of 
each lipoprotein bands were determined by multiplying the relative AUC of subfractions by 
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total cholesterol concentration of the sample. LDL-cholesterol (LDL-C) is calculated by an 
automatic way using the Lipoware software as the sum of the cholesterol concentrations of all 
the LDL subfractions plus the Midband A, B and C. Mean LDL size (nm) was also calculated 
by the Lipoware software. 
 
 HDL subfraction analysis 
 HDL subfractions were also detected by polyacrylamide gelelectrophoresis with the 
Lipoprint System (Quantimetrix Corp.). 25 μl of serum samples were added to 
polyacrylamide gel tubes along with 300 μl loading gel solution containing Sudan Black as 
lipophilic dye. After 30 min of photopolymerization at room temperature, electrophoresis was 
performed for 50 min with a 3 mA/gel tube.  
Stained HDL subfractions (bands) were identified by their mobility after 
electrophoresis. The LDL/VLDL band was the starting reference point (Rf 0.0) and albumin 
was the ending reference point (Rf 1.0). AUC% were calculated with the Lipoware computer 
software (Quantimetrix Corp.). Up to ten HDL subfractions, distributed between the 
LDL/VLDL and albumin bands were grouped into three major classes: large (HDL1 to 
HDL3), intermediate (HDL4 to HDL7) and small (HDL8 to HDL10) HDL subfractions.  
 
 Human paraoxonase-1 measurements 
PON1 paraoxonase activity was analyzed on a microtiter plate by a kinetic, 
semiautomated method utilizing paraoxon (O,O-diethyl-O-p-nitrophenyl-phosphate, Sigma 
Aldrich, Hungary) as a substrate. PON1 arylesterase activity was assayed with a 
phenylacetate substrate (Sigma Aldrich, Hungary) and the hydrolysis of phenylacetate was 
monitored at 270 nm (36).  
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 Statistical analyses 
Statistical analysis was performed by STATISTICA software (ver 8.0; StatSoft Inc., 
Tulsa, OK). The normality of data distribution was tested by Kolmogorov-Smirnov test. Data 
are presented by descriptive analysis (mean ± SD in case of normal distribution, or median 
(lower quartile – upper quartile) in case of non-normal distribution). Comparisons between 
groups were performed by Student’s paired t-test in case of normally distributed variables and 
by Mann-Whitney U-test in case of variables with non-normal distribution. Correlations 
between continuous variables were assessed by linear regression analysis using Pearson’s test. 
Results were considered significant at the level of p<0.05.  
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FIGURE LEGENDS 
Figure 1: Correlation between clinical severity scores and HDL-C levels in SLOS patients 
(n=11; r=-0.804; p=0.003) (a); Serum PON1 arylesterase activity in SLOS and healthy control 
children (*p=0.022; □ mean; box: mean ± standard deviation; whiskers: mean ± 1.96’standard 
deviation) (b). 
Figure 2: LDL subfraction profile in a typical SLOS patient (a) and in a healthy child (b). 
Figure 3: HDL subfraction profile in a typical SLOS patient (a) and in a healthy child (b). 
Table 1. Clinical and laboratory characteristics of the study participants 
SLOS, Smith-Lemli-Opitz syndrome; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; n.s., non-significant; n.d., non-detectable, <0.15 mg/L. 
Values are presented as mean ± standard deviation or median (lower quartile – upper quartile). 
 SLOS (n=11) Control (n=10) p 
Gender 4 girls / 7 boys 5 girls / 5 boys   
Age (years) 5.71 ± 6.93 5.36 ± 6.02 n.s. 
Clinical severity score 30.9 ± 15.1    
7-Dehydrocholesterol (mg/L) 205 (85-274) n.d.  
Total-Cholesterol (mmol/L) 1.73 ± 0.9 3.52 ± 0.63 <0.0001
LDL-C (mmol/L) 0.9 ± 0.4 1.88 ± 0.46 <0.0001
Large LDL (%) 16.9 (14.5-22.4) 26.1 (23.8-30.4) <0.001 
Small-dense LDL (%) 10.2 (2.3-13.3) 0.8 (0.0-2.7) <0.01 
Mean LDL size (nm) 25.7 ± 0.83 27.16 ± 0.32 <0.001 
LDL subfraction pattern      
 normal (n) 3 8  
 intermediate (n) 1 2  
 abnormal (n) 7 0  
HDL-C (mmol/L) 0.55 ± 0.38 1.04 ± 0.27 <0.01 
Large HDL (%) 73.5 (47.4-77.2) 34.5 (31.6-41.8) <0.001 
Intermediate HDL (%) 19.8 (18.9-39.6) 49.5 (44.3-50.5) <0.001 
Small HDL (%) 7.1 (2.3-11.0) 16.0 (13.9-18.5) <0.01 
Table 2. Correlations between serum PON1 arylesterase activity and lipoprotein parameters in all 
studied participants 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; n.s. 
non-significant
Variables r p 
Total-Cholesterol (mmol/L) 0.543 0.045 
LDL-C (mmol/L) 0.533 n.s. 
Large LDL (%) 0.349 n.s. 
Small-dense LDL (%) -0.578 0.031 
Mean LDL size (nm) 0.610 0.021 
HDL-C (mmol/L)  0.457 n.s. 
Large HDL (%) -0.798 0.001 
Intermediate HDL (%) 0.652 0.012 
Small HDL (%) 0.663 0.010 



